Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00876655 | Exploratory Pharmacokinetic and Bioavailability Study of 2 Capsule Formulations of Torezolid Phosphate | PHASE1 | COMPLETED | 12 | — | — | Feb 1, 2009 | Mar 1, 2009 | May 3, 2016 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| free acid | EXPERIMENTAL | TR-701 free acid phosphate powder in capsule formulation (equivalent to 150 mg TR-700) |
| di-sodium phosphate salt | EXPERIMENTAL | One 200 mg capsule of TR-701 di-sodium phosphate salt (equivalent to 150 mg TR-700) |
| Name | Type | Description |
|---|---|---|
| TR-701 di-sodium phosphate salt | DRUG | One 200 mg capsule of TR-701 di-sodium phosphate salt (equivalent to 150 mg TR-700) |
| TR-701 free acid phosphate | DRUG | One 182 mg capsule of TR-701 free acid phosphate (equivalent to 150 mg TR-700) |
Inclusion Criteria: * In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead ECG, and vital signs; * Females will be non-pregnant, non-lactating, and either postmenopausal for at least 1 year, surgically sterile for at least 90 days, or ...